Geoff Krampitz (@geoffkrampitz) 's Twitter Profile
Geoff Krampitz

@geoffkrampitz

Robotic surgical oncology, hepatopancreatobiliary, and general surgery

ID: 1130594573145792514

calendar_today20-05-2019 22:02:06

17 Tweet

134 Followers

207 Following

Geoff Krampitz (@geoffkrampitz) 's Twitter Profile Photo

The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL | Nature www-nature-com.proxy1.lib.tju.edu/articles/s4158…

Miriam Merad, MD, PhD (@miriammerad) 's Twitter Profile Photo

Today we celebrated the 80th Bday of Irv Weissman ! An incredible mentor who taught us to think big, enjoy the journey and be generous! The symposium’s talks given mostly by Irv’s progeny was a great tribute to his enormous legacy ! Happy Bday Irv !

Today we celebrated the 80th Bday of Irv Weissman ! An incredible mentor who taught us to think big, enjoy the journey and be generous! The symposium’s talks given mostly by Irv’s progeny was a great tribute to his enormous legacy ! Happy Bday Irv !
Geoff Krampitz (@geoffkrampitz) 's Twitter Profile Photo

Geoff Krampitz #lab is hiring a #postdoc at Jefferson Health Sidney Kimmel Comprehensive Cancer Center for translational/basic #science #research in #cancer #immunology #immunotherapy #precisionmedicine. #postdocs #postdocjob #labtechnician. Please apply online at: 1) TJU Careers…lnkd.in/ggHjeYa

Geoff Krampitz (@geoffkrampitz) 's Twitter Profile Photo

Post Doctoral Fellow - Lab of Dr. Geoffrey Krampitz job with Jefferson Health Philadelphia, Pennsylvania jobs.sciencecareers.org/job/506113/pos… #jobs

NEJM (@nejm) 's Twitter Profile Photo

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research